Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph not_applicable
3
43%
Ph phase_1
2
29%
Ph early_phase_1
2
29%

Phase Distribution

4

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Early Phase 1First-in-human
2(28.6%)
Phase 1Safety & dosage
2(28.6%)
N/ANon-phased studies
3(42.9%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 3 finished

Non-Completion Rate

100.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Terminated(3)
Other(4)

Detailed Status

Withdrawn3
Suspended2
unknown2

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
N/A
Most Advanced
Early Phase 1

Trials by Phase

Early Phase 12 (28.6%)
Phase 12 (28.6%)
N/A3 (42.9%)

Trials by Status

suspended229%
unknown229%
withdrawn343%

Recent Activity

0 active trials
Showing 5 of 7
suspendednot_applicable

Autologous Stem/Stromal Cellular Stromal Vascular Fraction (cSVF) In Frailty-Aging Processes

NCT03514537
suspendednot_applicable

Use of Stromal Vascular Fraction in Multiple Sclerosis

NCT03461419
unknownearly_phase_1

Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection

NCT04326036
withdrawnearly_phase_1

Use of Adipose-Derived Stem/Stromal Cells in Concussion and Traumatic Brain Injuries

NCT02959294
withdrawnphase_1

Use of Cellular Stromal Vascular Fraction in Multiple Sclerosis,Autoimmune, Inflammatory, Neurologic Conditions

NCT02939859
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT03514537Not Applicable

Autologous Stem/Stromal Cellular Stromal Vascular Fraction (cSVF) In Frailty-Aging Processes

Suspended
NCT03461419Not Applicable

Use of Stromal Vascular Fraction in Multiple Sclerosis

Suspended
NCT04326036Early Phase 1

Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection

Unknown
NCT02959294Early Phase 1

Use of Adipose-Derived Stem/Stromal Cells in Concussion and Traumatic Brain Injuries

Withdrawn
NCT02939859Phase 1

Use of Cellular Stromal Vascular Fraction in Multiple Sclerosis,Autoimmune, Inflammatory, Neurologic Conditions

Withdrawn
NCT02961114Phase 1

Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy

Withdrawn
NCT03297177Not Applicable

Autologous Stem/Stromal Cells in Neurological Disorders and Disease

Unknown

All 7 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
7